Drug Trial Radar · NCT00003907
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Last checked: Nov 20, 2026Latest source record: Jul 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Dec 15, 1999
Primary completion
May 2011
Study completion Aug 2012
Sponsor
- Lead sponsor
- Eastern Cooperative Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 9, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: Phase II trial to study the effectiveness of chemoembolization in treating patients who have primary liver cancer or metastases to the liver that cannot be surgically removed.
Conditions
- Liver Cancer
- Metastatic Cancer
Interventions
cisplatinDrug
Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
doxorubicinDrug
Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
mitomycinDrug
Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
embolizationProcedure
Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to ProgressionTime frame: Assessed every 3 months for 2 years, then every 6 months for 3 year.
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
Front Range Cancer Specialists
Fort Collins, Colorado
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Veterans Affairs Medical Center - Atlanta (Decatur)
Decatur, Georgia
Rush-Copley Cancer Care Center
Aurora, Illinois
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois
Hematology and Oncology Associates
Chicago, Illinois
Veterans Affairs Medical Center - Lakeside Chicago
Chicago, Illinois
Mercy Hospital and Medical Center
Chicago, Illinois
Swedish Covenant Hospital
Chicago, Illinois
Hinsdale Hematology Oncology Associates
Hinsdale, Illinois
Midwest Center for Hematology/Oncology
Joliet, Illinois
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois
North Shore Oncology and Hematology Associates, Limited - Libertyville
Libertyville, Illinois
Hematology Oncology Associates - Skokie
Skokie, Illinois
Hematology/Oncology of the North Shore at Gross Point Medical Center
Skokie, Illinois
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois
CCOP - Carle Cancer Center
Urbana, Illinois
Saint Anthony Memorial Health Centers
Michigan City, Indiana
Mercy Capitol Hospital
Des Moines, Iowa
CCOP - Iowa Oncology Research Association
Des Moines, Iowa
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa
Medical Oncology and Hematology Associates - West Des Moines
West Des Moines, Iowa
Borgess Medical Center
Kalamazoo, Michigan
West Michigan Cancer Center
Kalamazoo, Michigan
Bronson Methodist Hospital
Kalamazoo, Michigan
Carol G. Simon Cancer Center at Morristown Memorial Hospital
Morristown, New Jersey
Somerset Medical Center
Somerville, New Jersey
Overlook Hospital
Summit, New Jersey
Case Comprehensive Cancer Center
Cleveland, Ohio
St. Rita's Medical Center
Lima, Ohio
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania
Albert Einstein Cancer Center
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.